Stock ULTI ULTIMOVACS ASA
Add to a list
To use this feature you must be a member
Log inSign up

All News Ultimovacs ASA

Equities

ULTI

NO0010851603

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-06-21 EDT 		5-day change 1st Jan Change
7.85 NOK +0.64% Intraday chart for Ultimovacs ASA -9.04% -93.61%
06-11 Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma CI
05-07 Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma
CI
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
GL
Ultimovacs : INITIUM Poster presentation at ASCO, June 1, 2024
PU
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Ultimovacs : presentation per May 7, 2024
PU
Ultimovacs Q1 2024 - Survival mode
AQ
Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
GL
Ultimovacs ASA Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
GL
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
GL
Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments
MT
Transcript : Ultimovacs ASA - Special Call
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
AQ
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
GL
Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
CI
Ultimovacs - Invitation to Business Update on April 17, 2024
AQ
Ultimovacs – Invitation to Business Update on April 17, 2024
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ULTI Stock
  4. News Ultimovacs ASA